Mylan N.V. (NASDAQ:MYL) belonging to the Medical sector has declined -0.94% and closed its last trading session at $35.65.
The company reported its EPS on 11/09/2016. Currently, the stock has a 1 Year Price Target of $50.89.
The consensus recommendation, according to Zacks Investment research, is 1.83. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. The Stock had a 1.83 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 2.2 and 2.25 respectively.
Mylan N.V. on 11/09/2016 reported its EPS as $1.38 with the analysts projecting the EPS of the stock as $1.45. The company beat the analyst EPS Estimate with the difference of $-0.07. This shows a surprise factor of -4.8%.
Many analysts have provided their estimated foresights on Mylan N.V. Earnings, with 17 analysts believing the company would generate an Average Estimate of $1.43. Whereas they predicted High and Low Earnings Estimate as $1.53 and $1.38 respectively. While in the same Quarter Previous year, the Actual EPS was $1.22.
Analysts are also projecting an Average Revenue Estimate for Mylan N.V. as $3.19 Billion in the Current Quarter. This estimate is provided by 14 analysts. The High Revenue estimate is predicted as 3.27 Billion, while the Low Revenue Estimate prediction stands at 3.1 Billion. The company’s last year sales total was 2.49 Billion.
For the Current Quarter, the growth estimate for Mylan N.V. is 17.2%, while for the Next Quarter the stock growth estimate is 30.3%. In the past 5 years, the stock showed growth of 17.82% per annum. While for the next 5 years, the growth estimate is 9.04%.
The Company got Initiated by Mizuho on 26-Oct-16 to Buy.
Insider Trades for Mylan N.V. show that the latest trade was made on 8 Aug 2016 where Bresch (Heather M), the Chief Executive Officer completed a transaction type “Sell” in which 100200 shares were traded at a price of $50.
1 Insider Sales transactions were made totaling 8351 shares traded.
19 analysts projected Price Targets for Mylan N.V.. The analysts believe that the company stock price could grow as high as $59. The Low Price target projection by analysts is $43 and the Mean Price Target is $50.89.
Mylan N.V. (NASDAQ:MYL) has the market capitalization of $19.1 Billion. The company rocked its 52-Week High of $55.51 on Dec 29, 2015 and touched its 52-Week Low of $33.6 on Nov 3, 2016. The stock has Return on Assets (ROA) of 0.9 percent. Return on Equity (ROE) stands at 2.4% and Return on Investment (ROI) of 8.2 percent.
The stock is currently showing YTD performance of -34.07 Percent. The company has Beta Value of 1.08 and ATR value of 1.28. The Weekly and Monthly Volatility stands at 3.00% and 3.49%.
Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as Mylan Inc., is based in Canonsburg, Pennsylvania.